---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-042617"
form_type: "8-K"
ticker: "DSGN"
cik: "0001807120"
company_name: "Design Therapeutics, Inc."
filed_at: "2021-08-09T23:59:59+00:00"
generated_at: "2026-06-29T19:15:05.749549+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Design Therapeutics Q2 net loss $7.6M; FA GeneTAC on track for H1 2022 clinical start

## Summary
- Net loss $7.6M; R&D expenses $5.0M, G&A $2.7M; cash & investments $402.8M.
- Lead FA GeneTAC program: IND-enabling data support initiation of Phase 1 trial in H1 2022.
- Appointed Elizabeth Gordon, Ph.D., as SVP Regulatory Affairs; board expanded with Behanna & Prasad.
- DM1 GeneTAC program preclinical data planned for H2 2021.
- Well-tolerated FA GeneTAC doses in rodents/NHPs achieved CNS, heart, muscle concentrations above therapeutic threshold.

## SEC filing metadata
- accession: 0001564590-21-042617
- form_type: 8-K
- ticker: DSGN
- cik: 0001807120
- company_name: Design Therapeutics, Inc.
- filed_at: 2021-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1807120/000156459021042617/0001564590-21-042617-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1807120/000156459021042617/dsgn-8k_20210809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-042617
- JSON: https://secwatch.observer/filing/0001564590-21-042617.json
- Plain text: https://secwatch.observer/filing/0001564590-21-042617.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.